Document:

THE SECURITIES REPRESENTED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE TRANSFERRED OR SOLD
UNLESS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN AVAILABLE EXEMPTION FROM REGISTRATION.

 

	Number ___	_______ Shares

 

ARRAYIT
DIAGNOSTICS, INC. 

 

INCORPORATED
UNDER THE LAWS OF THE STATE OF nevada

 

This Certifies that ________________________________ 

 

is
the owner of _________________________________

FULLY
PAID AND NON-ASSESSABLE SHARES OF SERIES B PREFERRED stock, $.001 PAR VALUE, OF

 

Arrayit Diagnostics, Inc. transferable on the books of the
Company by the holder hereof in person or by duly authorized attorney upon surrender of this certificate properly endorsed.

 

Witness the original signatures of the Company’s duly
authorized officers.

  

Dated: ___________________

 

	

/s/ John Howell		/s/ John Howell
	John Howell, President	John Howell, Secretary

 

    	 

    	 

    

 

ASSIGNMENT

 

FOR VALUE RECEIVED the undersigned hereby
sells, assigns and transfers unto

  

PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING
NUMBER OF ASSIGNEE

 

 

(Please print or typewrite name and address, including postal
zip code, of assignee)

 

 

the within Certificate, and all rights
thereunder, hereby irrevocably constituting and appointing

 

 

Attorney to transfer said Certificate on
the books of the Certificate Registrar, with full power of substitution in the premises.

 

Dated:

 

	 	 
	 	Signature Guaranteed:
	 	 
	 	 

 

NOTICE: The signature to this assignment
must correspond with the name as it appears upon the face of the within Certificate in every particular, without alteration, enlargement
or any change whatever. Such signature must be guaranteed by a member firm of the New York Stock Exchange or a commercial bank
or trust company.PLAN AND AGREEMENT OF MERGER

 

MERGING

 

ARRAYIT DIAGNOSTICS (OVARIAN),INC.

 

INTO

ARRAYIT DIAGNOSTICS, INC. *****

 

THIS PLAN AND AGREEMENT OF MERGER is entered into as of the
23rd day of May 2011 by and between Arrayit Diagnostics (Ovarian), Inc., a Nevada corporation ("Ovarian")
and Arrayit Diagnostics, Inc., a Nevada corporation for the purpose of merging Ovarian with and into Diagnostics.

 

WHEREAS, Diagnostics owns all the issued and outstanding shares
of capital stock of Ovarian;

 

WHEREAS, the laws of the State of Nevada permit the merger of
a wholly owned subsidiary corporation of said State into a parent corporation organized and existing under the laws of another
State.

 

WHEREAS, Diagnostic, Ovarian and the respective boards of directors
thereof declare it advisable and to the advantage, welfare, and best interests of said corporations and their respective stockholders
to merge Ovarian with and into Diagnostics pursuant to the provisions of the Nevada Revised Statutes upon the terms and conditions
hereinafter set forth;

 

NOW, THEREFORE, in consideration of the premises and of the
mutual agreement of the parties hereto hereby determine and agree as follows.

 

1.          Ovarian
shall, pursuant to the provisions of the Nevada Revised Statutes, be merged with and into Diagnostics, which shall be the surviving
corporation from and after the effective time of the merger and which is sometimes hereinafter referred to as the "surviving
corporation", and which shall continue to exist as said surviving corporation under its present name pursuant to the provisions
of the Nevada Revised Statutes. The separate existence of Ovarian, which is sometimes hereinafter referred to as the "terminating
corporation", shall cease at said effective time in accordance with the provisions of the Nevada Revised Statutes.

 

2.          The
present Articles of Incorporation of the surviving corporation will be the Articles of Incorporation of the surviving corporation
and will continue in full force and effect until changed, altered, or amended as therein provided and in the manner prescribed
by the provisions of the Nevada Revised Statutes.

 

3.          The
present bylaws of the surviving corporation will be the bylaws of said surviving corporation and will continue in full force and
effect until changed, altered, or amended as therein provided and in the manner prescribed by the provisions of the Nevada Revised
Statutes.

 

4.          The
directors and officers in office of the surviving corporation at the effective time of the merger shall be the members of the Board
of Directors and the officers of the surviving corporation, all of whom shall hold their directorships and offices until the election
and qualification of their respective successors or until their tenure is otherwise terminated in accordance with the by-laws of
the surviving corporation.

 

5.          The
surviving corporation may sue in any court with jurisdiction to cause any stockholder of the terminating corporation to tender
certificates representing shares owned by such stockholder to be tendered to the surviving corporation for exchange. Stockholders
of the terminating corporation shall have no rights to notices, distributions or voting with respect to the surviving corporation
unless the certificates representing shares of the terminating corporation are tendered to the surviving corporation for exchange.

 

6.          The
Board of Directors and the proper officers of the terminating corporation and of the surviving corporation are hereby authorized,
empowered, and directed to do any and all acts and things, and to make, execute, deliver, file, and record any and all instruments,
papers, and documents which shall be or become necessary, proper, or convenient to carry out or put into effect any of the provisions
of this Plan and Agreement of Merger or of the merger herein provided for.

 

    	 

    	 

    

 

7.          The
effective time of this Plan and Agreement of Merger, and the time at which the merger herein agreed shall become effective a certificate
of merger meeting the requirements of the Nevada Revised Statutes, is filed with the Secretary of State of the State of Nevada.

 

IN WITNESS WHEREOF, said Diagnostic and
Ovarian have caused this Plan and Agreement of Merger to be executed on behalf of each as the date first above written.

 

	Arrayit Diagnostics, Inc.	 
	 	 
	By:	/s/ John Howell	 
	 	John Howell, President	 
	 	 
	Arrayit Diagnostics (Ovarian), Inc.	 
	 	 
	By:	/s/ John Howell	 
	 	John Howell, PresidentTECHNOLOGY ASSIGNMENT AGREEMENT

 

This Agreement is entered as of July
18th, 2009, between Arrayit Diagnostics, Inc., a Nevada corporation (“Company”), and Arrayit Corporation, a Nevada
corporation (“Developer”).

 

1.          Assignment.
The Developer hereby assigns to the Company, exclusively throughout the world, all right, title, and interest (choate or inchoate)
in (i) the subject matter referred to in Exhibit A (“Technology”), (ii) all precursors, portions and work in progress
with respect thereto and all inventions, works of authorship, mask works, technology, information, know-how, materials, and tools
relating thereto or to the development, support, or maintenance thereof and (iii) all copyrights, patent rights, trade secret rights,
trademark rights, mask works rights, sui generis database rights, and all other intellectual and industrial property rights of
any sort and all business, contract rights, causes of action, and goodwill in, incorporated or embodied in, used to develop, or
related to any of the foregoing (collectively “Intellectual Property”).

 

2.           Consideration.
In consideration of the assignment of the intellectual Property, the Company agrees to issue to the Developer 80% of the Company’s
issued and outstanding shares of capital stock (the “Shares”) existing as of the date hereof. The Shares shall be the
only consideration required of the Company with respect to the subject matter of this Agreement.

 

3.            Further
Assurances; Moral Rights; Competition; Marketing.

 

3.1          The
Developer agrees to assist the Company in every legal way to evidence, record, and perfect the assignment set forth in Section
1 and to apply for and obtain recordation of and from time to time enforce, maintain, and defend the assigned rights.

 

3.2          To
the extent allowed by law, the assignment of the Intellectual Property in Section 1 includes all rights of integrity, disclosure,
and withdrawal and any other rights that may be known as or referred to as “moral rights,” “artist’s rights,”
“droit moral” or the like (collectively “Moral Rights”). To the extent the Developer retains any such Moral
Rights under applicable law, the Developer hereby ratifies and consents to, and provides all necessary ratifications and consents
to, any action that may be taken with respect to such Moral Rights by or authorized by Company and the Developer agrees not to
assert any Moral Rights with respect thereto. The Developer will confirm any such ratifications, consents, and agreements from
time to time as requested by Company. The Developer also agrees not to sue or challenge in any manner, the validity of the assignment
set forth in this Agreement and the Company’s rights to the Intellectual Property set forth hereunder.

 

4.           Warranty.
The Developer represents and warrants to the Company that the Developer: (i) is the sole owner (other than the Company) of all
rights, title, and interest in the Intellectual Property and the Technology; (ii) has not assigned, transferred, licensed, pledged,
or otherwise encumbered any Intellectual Property or the Technology or agreed to do so, other than to the Company’s lenders
in the normal course of business; (iii) has full power and authority to enter into this Agreement and to make the assignment as
provided in Section 1; (iv) is not aware of any violation, infringement, or misappropriation of any third party’s rights
(or any claim thereof) by the Intellectual Property or the Technology; (v) was not acting within the scope of employment by any
third party when conceiving, creating, or otherwise performing any activity with respect to anything purportedly assigned in Section
1; (vi) is not aware of any questions or challenges with respect to the patentability or validity of any claims of any existing
patents or patent applications relating to the Intellectual Property; (vii) has been granted the opportunity to ask questions of
and receive answers from representatives of the Company concerning the terms and conditions of the Shares and to obtain any additional
information concerning the Company or the Shares that the Developer deems necessary in connection with his decision to assign the
Intellectual Property; (viii) is capable of evaluating the risks of owning the Shares; (ix) is an “Accredited Investor”
within the meaning of Regulation D promulgated pursuant to the Federal Securities Act; and (x) has adequate means of providing
for his current financial needs, including possible future personal financial contingencies.

 

5.          Miscellaneous.
This Agreement is not assignable or transferable by the Developer without the prior written consent of the Company; any attempt
to do so shall be void. The terms and provisions hereof shall inure to the benefit of and be binding upon the Company and its respective
successors and assigns. Any notice, report, approval, or consent required or permitted hereunder shall be in writing and will be
deemed to have been duly given if delivered personally or mailed by first-class, registered or certified U.S. mail, postage prepaid
to the respective addresses of the parties as set forth below (or such other address as a party may designate by ten (10) days’
notice). No failure to exercise, and no delay in exercising, on the part of either party, any privilege, any power, or any rights
hereunder will operate as a waiver thereof, nor will any single or partial exercise of any right or power hereunder preclude further
exercise of any other right hereunder. If any provision of mis Agreement shall be adjudged by any court of competent jurisdiction
to be unenforceable or invalid, that provision shall be limited or eliminated to the minimum extent necessary so that this Agreement
shall otherwise remain in full force and effect and enforceable. This Agreement shall be deemed to have been made in, and shall
be construed pursuant to the laws of the State of Texas and the United States without regard to conflicts of law provisions thereof.
The prevailing party in any action to enforce this Agreement shall be entitled to recover costs and expenses including, without
limitation, attorneys’ fees. The terms of this Agreement are confidential to the Company and no press release or other written
or oral disclosure of any nature regarding the compensation terms of this Agreement shall be made by the Developer without the
Company’s prior written approval; however, approval for such disclosure shall be deemed given to the extent such disclosure
is required to comply with governmental rules. Any waivers or amendments shall be effective only if made in writing and signed
by a representative of the respective parties authorized to bind the parties. Both parties agree that this Agreement is the complete
and exclusive statement of the mutual understanding of the parties and supersedes and cancels all previous written and oral agreements
and communications relating to the subject matter of this Agreement.

 

    	1

    	 

    
 

          IN WITNESS WHEREOF, the parties have executed this Agreement
on the day and year first indicated above.

 

	ARRAYIT CORPORATION	 	ARRAYIT DIAGNOSTICS, INC.
	 	 	 	 	 
	By:	/s/ Rene’ A. Sehena	      	By:	/s/ John Howell
		Rene’ A. Sehena, Chairman and Chief Executive Officer	 	 	John Howell, President

 

    	2

    	 

    

 

EXHIBIT A TO TECHNOLOGY
ASSIGNMENT AGREEMENT

TECHNOLOGY CONTRIBUTED BY DEVELOPER

 

Developer assigns to Company all of the trade secrets and
protocols required for the production and use the ovarian cancer biomarker panel for early stage (pre-symptomatic) screening and
detection of ovarian cancer and monitoring of early and late stage ovarian cancer in human patients, including printed microarray
substrates containing ovarian biomarkers; hardware required for ovarian biomarker microarray use; reagents required for microarray
processing, washing and staining; data quantification and reporting software for reference laboratory, point-of-care, and site-of-care
use; pre-packaged kits for reference laboratory, point-of-care and site-of-care use; and any improvements or modifications to the
ovarian test made by Developer.

 

This assignment does not imply any assignment of U.S. Patents
6,101,946 or 6,913,879 or their issued or pending foreign equivalents owned by Developer.

 

This assignment does not limit Developer from using identical
or similar trade secrets and protocols for disease tests other than ovarian cancer.

 

Under the terms of this assignment,
it is understood that Company will license biomarkers from third parties and make them available to Developer for printing.

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]